CINRYZE with rHuPH20
0624-206
Phase 2 mab completed
Quick answer
CINRYZE with rHuPH20 for Hereditary Angioedema (HAE) is a Phase 2 program (mab) at Takeda with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Takeda
- Indication
- Hereditary Angioedema (HAE)
- Phase
- Phase 2
- Modality
- mab
- Status
- completed